{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"29"}],"units":"Participants"}],"description":"Incidence of uterine endometrial stromal sarcomas as assessed by sonogram/biopsy (females)","groups":[{"description":"This was a follow-up safety study where study treatment was not administered. Patients came from BGG492 studies where patients were previously exposed to \\> 28 days of BGG492 50 mg, 100 mg or 150 mg given orally three times a day","id":"OG000","title":"BGG492"}],"paramType":"NUMBER","populationDescription":"Full Analysis Set (FAS):included all patients who signed informed consent to enter the study, but this assessment was only done on female patients. Of the 31 female patients, two had a hysterectomy and were not evaluated (N=29)","reportingStatus":"POSTED","timeFrame":"Minimum of one year after last dose of BGG492 in study BGG492A2207 or BGG492A2212","title":"Incidence of Uterine Endometrial Stromal Sarcomas","type":"PRIMARY","unitOfMeasure":"Participants"}